📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Alto Neuroscience

1.1 - Company Overview

Alto Neuroscience Logo

Alto Neuroscience

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of an AI-driven biomarker platform that integrates patients’ brain activity and behavior to identify likely responders and enable precision medicines, plus a clinical-stage pipeline for neuropsychiatric conditions, including ALTO-100 (BDNF) for MDD/PTSD, ALTO-300 for MDD, ALTO-202 (NMDA NR2B) for MDD/PTSD, and ALTO-101 (PDE4) for schizophrenia and other neuropsychiatric conditions.

Products and services

  • AI-driven biomarker platform: AI-enabled platform that combines patients’ brain activity and behavior to identify likely responders to novel product candidates and drive precision patient stratification
  • Clinical stage product candidates: Biomarker-stratified pipeline of neuropsychiatric products that uses patient biomarkers to identify responders for MDD, PTSD, schizophrenia, and other neuropsychiatric conditions
  • ALTO-202: NR2B-selective product candidate targeting NMDA receptors for MDD and potentially PTSD, engineered to modulate NMDA NR2B subunits

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Alto Neuroscience

Inscopix Logo

Inscopix

HQ: United States Website
  • Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Inscopix company profile →
Aruna Bio Logo

Aruna Bio

HQ: United States Website
  • Description: Provider of neural exosome-based therapies for central nervous system and neurodegenerative disorders; developer of AB126, a therapeutic neural cell-derived exosome that crosses the blood-brain barrier to reduce neuro-inflammation, promote neuro-protection, and stimulate neuro-regeneration, plus a CNS therapeutic platform and pipeline; also conducts research in stem cells, neural stem cells, and drug toxicity assays.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aruna Bio company profile →
Braeburn Logo

Braeburn

HQ: United States Website
  • Description: Provider of opioid use disorder solutions, including BRIXADI, a weekly and monthly injectable medication for moderate to severe OUD, and an Investigator-Initiated Trials program that supports independent research to advance medical and scientific understanding of its products and related therapeutic areas.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Braeburn company profile →
Avanir Pharmaceuticals Logo

Avanir Pharmaceuticals

HQ: United States Website
  • Description: Provider of biopharmaceutical medicines for central nervous system disorders, focused on high unmet medical need. Offers Nuedexta, a medication used to treat pseudobulbar affect (PBA), characterized by sudden, uncontrollable episodes of crying or laughing. Extensively invests in its pipeline and is dedicated to advancing medicines that can substantially improve patients' lives.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Avanir Pharmaceuticals company profile →
Tris Pharma Logo

Tris Pharma

HQ: United States Website
  • Description: Provider of specialty generic pharmaceuticals leveraging its LiquiXR drug delivery technology for sustained-release formulations, including ADHD treatments with flexible dosing for patients aged 6+, a portfolio of 10 generic products with 20+ in development, technology licensing of its delivery technologies, and partnerships to enhance product development and commercialization.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tris Pharma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Alto Neuroscience

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Alto Neuroscience

2.2 - Growth funds investing in similar companies to Alto Neuroscience

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Alto Neuroscience

4.2 - Public trading comparable groups for Alto Neuroscience

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Alto Neuroscience

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Alto Neuroscience

What does Alto Neuroscience do?

Alto Neuroscience is a provider of an AI-driven biomarker platform that integrates patients’ brain activity and behavior to identify likely responders and enable precision medicines, plus a clinical-stage pipeline for neuropsychiatric conditions, including ALTO-100 (BDNF) for MDD/PTSD, ALTO-300 for MDD, ALTO-202 (NMDA NR2B) for MDD/PTSD, and ALTO-101 (PDE4) for schizophrenia and other neuropsychiatric conditions.

Who are Alto Neuroscience's competitors?

Alto Neuroscience's competitors and similar companies include Inscopix, Aruna Bio, Braeburn, Avanir Pharmaceuticals, and Tris Pharma.

Where is Alto Neuroscience headquartered?

Alto Neuroscience is headquartered in United States.

How many employees does Alto Neuroscience have?

Alto Neuroscience has 1,000 employees 🔒.

When was Alto Neuroscience founded?

Alto Neuroscience was founded in 2010 🔒.

What sector and industry vertical is Alto Neuroscience in?

Alto Neuroscience is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Alto Neuroscience

Who are the top strategic acquirers in Alto Neuroscience's sector and industry

Top strategic M&A buyers and acquirers in Alto Neuroscience's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Alto Neuroscience?

Top strategic M&A buyers groups and sectors for Alto Neuroscience include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Alto Neuroscience's sector and industry vertical

Which are the top PE firms investing in Alto Neuroscience's sector and industry vertical?

Top PE firms investing in Alto Neuroscience's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Alto Neuroscience's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Alto Neuroscience's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Alto Neuroscience's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Alto Neuroscience include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Alto Neuroscience's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Alto Neuroscience?

The key public trading comparables and valuation benchmarks for Alto Neuroscience include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Alto Neuroscience for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Alto Neuroscience with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Alto Neuroscience's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Alto Neuroscience with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Alto Neuroscience's' sector and industry vertical?

Access recent funding rounds and capital raises in Alto Neuroscience's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Alto Neuroscience